Chinese Hepatolgy ›› 2016, Vol. 21 ›› Issue (1): 2-5.

• Orginal Articles • Previous Articles     Next Articles

Assessment of SF-36 scale in life quality of compensated HBV-related cirrhosis patients improved by antiviral therapy and its related indicators

WEI Wei, YIN Ji-peng, LI Han, KONG Yuan-yuan, WU Xiao-ning, ZHOU Jia-ling, SUN Dong-yang, SUN Ya-meng, YOU Hong, JIA Ji-dong   

  1. Clinical Epidemiology and Evidence Based Medicine Center,Beijing Friendship Hospital,Capital Medical University,National Clinical Research Center for Digestive Diseases,Beijing 100050,China
  • Received:2015-09-10 Published:2020-06-01
  • Contact: JIAJi-dong,Email：jiamd@263.net

PDF (PC)

329

Abstract: Objective To investigate feasibility of SF-36 scale in assessing the life quality of compensated hepatitis Bvirus（HBV）-related cirrhosis patients im proved by different anti-viral strategies and its related indicators.Methods Atotal of 405 compensated HBV-related cirrhosis patients were divided into Monotherapy group（entecavir 0.5 Mg,qd）and combination group（adefovir 10 Mg,lamivudine 100 Mg,qd）according to their healthy condition and financial status. During 104 weeks of treatment,HBVDNAload,Fibroscan,levels of alanine aminotransferase（ALT）,aspartate transaminase（AST）and other related indicators were recorded,and SF-36 scale was performed to assess patients'life quality. Results At the end of follow-up,life quality of these patients was im proved（F=10.78,P<0.01）,which was related to HBVDNAload（r=-0.647,P=0.030）,Fibroscan（r=-0.485,P=0.047）and ALT/ AST（r=-0.356,P=0.022）at baseline. Conclusion Different antiviral treatments could im prove life quality of compensated HBV-related cirrhosis patients,which is related to so me antiviralindicators.

Key words: compensated HBV-related cirrhosis, SF-36, Antiviral therapy